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Summary 
Glioblastoma Multiforme (GBM) is the most common and lethal of human primary central 
nervous system (CNS) tumors. Due to the tumour’s intrinsic clinical and molecular 
heterogeneity, choice of initial treatment, prediction of survival, stratification of patients, 
prediction and monitoring of response to therapy, represent some of the greatest challenges in 
the management of GBM patients. Patients, despite optimal surgery, radiation and 
chemotherapy, still have a median survival of 14-16 months. A reason for this dismal 
prognosis is because of the relative inaccuracy of current prognostic markers, so far based on 
clinical or pathological variables. Molecular markers that effectively predict response to 
therapy and survival outcomes are limited. Consequently, there is a strong need to develop 
novel and independent markers of prognosis. Ideal biomarkers for solid tumors would serve 
one or more important functions. Telomeres, guanine-rich tandem DNA repeats of the 
chromosomal end, provide chromosomal stability, regulates important cellular processes, and 
seem to be implicated in human carcinogenesis. Recently, telomeres have been shown either 
to be associated with clinical markers of disease progression or to be independent markers of 
cancer prognosis in solid tumours, including GBM. Nevertheless, a corresponding 
comprehensive discussion of these promising developments in brain tumours has not yet been 
available in the literature. Therefore, here we reviewed studies focused on the assessment of 
telomeric length in brain tumours with the aim to emphasized those findings indicating a 
potential clinical role of telomeres in GBM. With the aim to enhance the awareness of the 
potential clinical role of telomeres’ length information in GBM, using a southern blot 
analysis, telomeric length in excised tumour samples was analyzed. Moreover, an attempt to 
correlated telomere length with patients’ overall survival, was also performed. The findings 
here reviewed shows some contradictory results, due to different tissues used as controls, but 
mainly to cellular and molecular heterogeneity in GBMs that drive molecular mechanisms 
controlling telomere length, included telomerase and Alternative Lengthening of Telomeres 
(ALT), through multiple mechanisms. However, overall these studies, including our own, are 
consistent with the hypothesis that GBMs’ telomeres were always shorter when compared 
with Normal Brain Tissue (NBT), and together with higher telomerase activity seem to be 
associated with malignancy and poor outcome; while tumours with ALT phenotype have 
longer telomeres, “less malignant” behaviour and better prognosis. We conclude that, 
although not entirely consistent in the type of telomere alteration, i.e., attrition vs. elongation, 
and unclear on the underlying mechanisms, multiple studies in brain tumours have shown that 
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telomere dysfunctions are associated with parameters of clinical outcome in patients with 
GBMs and therefore will be part of novel risk assessment and prognostic modalities for 
patients with these still dismal disease. 
 
Key Words: Telomere length, Glioblastoma multiforme, Glioma, Brain tumor, prognostic 
marker. 
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INTRODUCTION 
 
Gliomas are a heterogeneous group of malignancies with highly variable outcomes. 
Pathological diagnosis is largely based on the histological appearance of the tumours. Despite 
notable recent achievements in oncology, malignant gliomas such as glioblastoma multiforme 
(GBM) present some of the greatest challenges in the management of cancer patients 
worldwide. Glioblastoma is the most common primary brain tumour in humans (1) and has 
the most severe prognosis (2, 3). Even with aggressive surgical resections using state-of-the-
art preoperative and intraoperative neuroimaging, along with recent advances in radiotherapy 
and chemotherapy, the prognosis for GBM patients remains dismal: median survival after 
diagnosis is about 15 months (4). So far, the most useful prognostic tools in this disease 
remain clinical indices such as age, the Karnofsky Performance Status (KPS) score and the 
histopathologic grade, as was reported in the recursive partitioning analysis performed by the 
Radiation Therapy Oncology Group (RTOG) (5), as well as the Ki-67 proliferative index. 
However, the heterogeneity of gliomas has made prognostic determinations, based purely on 
clinicopathologic variables, difficult. Recently, attempts to categorize GBM according to the 
response to chemotherapy were proposed. Inactivity of the O6-methylguanine-DNA 
methyltransferase seems to increase the responsiveness of GBMs to alkylating agents. 
However, the O6-methylguanine-DNA methyltransferase promoter is methylated in only 
45% of GBM (4, 6). EGFR and p53 are molecular markers that show promise as prognostic 
indicators of recurrence-free and overall survival in patients with GBMs, but further 
prospective studies are needed to confirm the retrospective findings. Postsurgical evaluation 
of these markers is potentially helpful in planning follow-up and treatment for these patients. 
Tumours expressing relatively high levels of these markers require closer follow-up and, 
when possible, more aggressive therapies. Despite intensive investigation into the expression 
Translational Medicine @ UniSa, - ISSN 2239-9747 2011, 1(1): 243-270 
 
247 
Università degli Studi di Salerno 
of molecules regulating apoptosis in brain tumours, no evidence presently exists to support 
their usefulness as markers of patient outcome (7). Although GBM is one of the best-studied 
brain tumor in terms of genetics and molecular prognostic factors, the true prognostic 
significance of all potential factors under investigation remain to be clarified. Therefore, the 
absence of reliable biological markers allowing the assessment of the evolution and prognosis 
of these tumours remains a major impediment to the clinical management of those patients. It 
has recently been speculated that changes in telomere domain can result in genetic disorders, 
genomic variability and, cell immortalization (8). Telomeres consist of long tandem arrays of 
TTAGGG repeats bound by proteins collectively termed the shelterin complex, placed at the 
end of linear chromosomes, which are involved in several essential biological functions (9, 
10). Functional telomeres protect chromosome ends from recombination and fusion, and are 
therefore essential for maintenance of chromosomal stability (9, 11, 12). Telomere 
dysfunction occurs as a result of critical shortening of telomeres, followed by sequential 
bridge–fusion–breakage cycles, leading to numerical chromosomal abnormalities (13, 14). 
Chromosomal instability is a phenotype that induces widespread genetic alterations, which 
may play critical roles in human carcinogenesis. The phenomenon of telomere alteration 
during tumorigenesis process and progression of solid tumors is well known and established 
at the molecular level. Cells exhibiting telomere dysfunction, with critical shortening and 
genomic instability, increase in both the formation of dicentric chromosomes and 
susceptibility to oncogenic transformation (15, 16, 17). Telomerase is a complex of a reverse 
transcriptase protein encoded by the TERT (telomerase reverse transcriptase) gene and a 
template RNA TERC (telomerase RNA component). Telomerase can add telomeric repeats 
onto the chromosome ends, and prevents the replication-dependent loss of telomere and 
cellular senescence in highly proliferative cells of the germline and in the majority of cancers 
(18). Thus, telomerase activity and telomere maintenance are associated with the immortality 
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of cancer cells, germ-line cells, and embryonic stem (ES) cells (19). The presence of 
telomerase RNA or telomerase activity appears to correlate with degree of malignancy in 
multiple types of brain tumors, including gliomas; however, it currently has no use as an 
independent prognostic indicator of patient outcome (7). It may instead be a marker for 
malignant tumor initiation or progression (7). Instead, the relationship between telomere 
maintenance, genomic instability and the resulting phenotypic variability that gives rise to 
cell clones that cause disease recurrence is well accepted (20, 21). Also, the potential clinical 
use of telomere length information for the prognosis of solid tumours has been recognized 
and continues to be validated (22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33). Here, we 
analyzed telomeres length in 15 glioblastoma samples obtained in vivo. Moreover, an attempt 
to correlate telomere length with patients’ survival was made. Finally, to increase our 
awareness of the potential clinical role of telomeres’ length information in glioblastoma, we 
reviewed, on the light of the recent literature, studies indicating the prognostic potential of 
telomeres in GBM. Excluded from this discussion studies focused on the use of telomerase, 
the enzyme implicated in telomere maintenance, as a biomarker for diagnosis or prognosis in 
brain tumours, a research area that also has been previously reviewed (34). The purpose of 
our study was to better define possible clinical significance of telomere dysfunctions in this 
disease.
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MATERIALS AND METHODS 
 
Patient population 
This study included tumors samples, histologically verified as GBMs, obtained in adult 
patients who underwent craniotomy for microsurgical tumor resection, at the Department of 
Neurosurgery of the University of Messina. All tumors were located in the supratentorial 
compartment. Only patients who had undergone large, gross total resection of their 
neoplasms (more than 95 % of the tumor volume) were eligible for the study. All patients 
underwent Temozolomide chemotherapy (75 mg/m(2)/d x 7 d/wk for 6 weeks) administered 
orally concomitant with fractionated radiotherapy (60 Gy total dose: 2 Gy x 5 d/wk for 6 
weeks) followed by temozolomide monotherapy (200 mg/m(2)/d x 5 days, every 28 days for 
six cycles). Samples obtained from single or multiple stereotactic biopsies were not included 
in the present study. We carefully excluded tumors containing components that were 
suspicious of oligodendroglioma. No case of recurrent tumors and no patient who underwent 
adjuvant therapy (radio and/or chemotherapy) before surgery were employed in the present 
study. Study included 9 men and 6 women whose mean age was of 66.66 ± 4.7 years, 
Karnofsky Performance Status (KPS) at the admission of 88.6 ± 9.1  and a mean survival 
period of 63.7 ± 17.3 weeks. 
 
Tissue Samples 
All tumor tissue samples were obtained from resection specimens, within 15 minutes from 
surgical tissue removal. Specimens were taken from viable areas of tumor, avoiding areas of 
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gross necrosis and three to seven anatomically separate areas of tumor tissue were sampled 
from each resection specimen, according to the volume of excised tissue available. Tissue 
samples for the histological, immunohistochemical, and telomere length analysis were taken 
from the same general region of the tumor during surgery. Tissue was placed in cryovials and 
immediately flash-frozen in liquid nitrogen in the operating room and stored at – 70° C. Both 
the adjacent tissue samples matched to the frozen tissue, as well as additional tissue 
submitted in toto from the resection specimens, were used for histological typing and 
grading. 
 As controls three samples of normal brain tissue (NBT) were used. Non-neoplastic brain 
tissue samples were derived from the temporal lobes of patients surgically treated for 
temporal lobe epilepsy and included histologically verified normal cortex and white matter. 
 
Telomere length analysis 
Genomic DNA was extracted from tumour specimens using standard method 
phenol/chloroform. Terminal Restriction Fragments (TRF) mean length measurement was 
performed using Telo TTAGGG Telomere Length Assay kit (Roche Molecular 
Biochemicals, Mannhein, Germany) as previously described (35). Briefly, genomic DNA (2 
µg) was digested with HinfI and RsaI, separated by agarose gel electrophoresis, transferred to 
a nylon membrane, and hybridized with a digoxigenin-labeled telomere-specific probe. 
Following to analysis, the TRF length was determined as the ratio of the length of tumor 
tissue TRF and their paired normal tissue TRF (ratio T/N). All cases in which T/N ratio 
resulted <1 were considered into the group of telomere shortening. When T/N was ≥1, tumors 
were considered in the group of telomere maintenance.  
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Statistical analysis 
The Pearson test was used to obtain correlation values among numerical variables. Data 
analysis was performed with INSTAT, v. 3.0, and PRISM, v. 4.0 (GraphPad, San Diego, 
Calif ). A probability value less than .05 was considered statistically significant. All values 
are expressed as the means ± SD. 
TABLE 1. 













1 57/F R-FP 6 90 42 9.30 
2 62/M R-FP 7 100 40 10,15 
3 68/M L-O 3 100 38 10,05 
4 64/F R-P 7 90 54 9,95 
5 68/M L-PT 5 100 58 9,75 
6 67/F R-FT 11 70 58 9,35 
7 65/M R-O 10 70 60 9,35 
8 69/M L-FP 8 80 62 9,15 
9 73/F R-PO 4 90 66 9,13 
10 71/M R-TP 1 90 68 9 
11 76/M R-F 3 90 68 8,93 
12 68/M R-T 3 90 74 8,76 
13 67/F L-FT 2 90 78 8,75 
14 62/M R-F 8 90 92 8,65 
15 63/F L-F 5 90 98 8,56 
N.B.T. - - - - - 10.93 
 
Abbreviations used: M: male; F: female; L: left; R: right; F: frontal; P: parietal; T: temporal; O: occipital; KPS: 
Karnofsky Performance Scale; kb: Kilobase; N.B.T.: normal brain Tissue.
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RESULTS 
Patients’ clinical and molecular parameters are summarized in Table 1. Telomere length was 
measured by Southern blot analysis in primary, untreated glioblastoma samples and in 
matched normal tissue TRF (ratio T/N) from 5 patients. Telomeres length was determined as 
the ratio of the length of tumor tissue TRF and their paired normal tissue TRF (ratio T/N). All 
cases in which T/N ratio resulted <1 were considered into the group of telomere shortening. 
When T/N was ≥1, tumors were considered in the group of telomere maintenance. Changes in 
telomere length, compared with their paired normal brain tissue, were observed in all tumors; 
were shorter in 13 of 15 tumours (86.66%). While telomeric length in 2 tumors (13.33%), 
was considered unchanged. The average telomere lengths in tumor samples set were lower 
compared with the normal brain tissues. In the present study the average telomere length was 
8.66 ± 2.34 Kbs in GBMs; while was 10.93± 2.35 Kbs in NBT. To define possible clinical 
significance of above mentioned findings, telomeres’ length was correlated with patients’ 
survival. Using a linear regression analysis an inverse correlation between telomere length 
and patients’ survival was found (P < 0.01). (Table 1) 
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DISCUSSION 
In the present study telomeric length in excised glioblastoma samples was analysed with the 
aim to contribute to the understanding of the role of telomere maintenance in brain tumours. 
Moreover, a systematic review of literature focused on the assessment of telomeric length in 
GBMs was performed. Our results demonstrate that telomere length varied among GBM 
samples but was always shorter as compared with normal brain tissues. The average telomere 
length was 8.66 ± 2.34 Kbs in GBM samples; while was 10.93± 2.35 Kbs in NBT. We also 
demonstrated an inverse correlation between telomere length and patients’ overall survival, 
suggesting a possible clinical role of telomere maintenance in glioblastoma. Our findings are 
in agreement with many authors studying telomeric length in different solid tumors, including 
breast, lung, colorectal, and head and neck cancers. Most of these studies suggest that in 
neoplastic tissue, telomeres are shorter when compared with normal tissue (22, 23, 24, 25, 26, 
28, 29, 32, 33) and thus confirming the hypothesis that telomere shortening may represent an 
early event in carcinogenesis. It is noteworthy that in almost all these studies telomere 
attrition is also associated with parameters of increased risk and poor outcome in human 
cancers. In the present studies, telomere attrition was observed in 13 of 15 tumours (86.66%). 
While, in 2 tumours (13.33%), telomere length was considered unchanged. Noteworthy, the 
latter were those patients with worse overall survival. Therefore, we compare telomere length 
and patients survival to verify possible correlation between telomere length and survival in 
GBM patients. Using a linear regression analysis an inverse correlation between telomere 
length and patients’ survival was found (P < 0.01). These findings may suggest that relative 
increase of telomere length in a subset of GBM patients was associated with worse prognosis. 
Our findings are in concert with those reported for colorectal and lung cancer, in which 
increased TRF correlated with higher tumour stage, and decreased overall survival; but are in 
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contrast to other studies reporting as reduced TRF was correlated with advanced stages in 
different cancer type, including breast and prostate cancers. One explanation for this 
discrepancy might lie in a potential tissue-specific pattern of telomere dysfunction that may 
reflect the underlying biology of telomere maintenance and its alteration over time in specific 
tissues. The latter is, for example, the case for normal colorectal epithelium that contain 
telomerase-positive cells of possible stem cell origin and presumably counteract telomere 
attrition due to physiologically high cell proliferation rates, and total cell loss due to 
physiological shedding in this specialized cell compartment (36). Thus it is possible that 
chromosomal instability and genetic disorders, due to telomere dysfunction, may affect the 
molecular key players of telomere maintenance, resulting in elongated telomeres in tumours. 
Telomeric DNA consists of short guanine-rich repeat sequences in all eukaryotes with linear 
chromosomes, and its length in human somatic cells is remarkably heterogeneous among 
individuals ranging from 5 to 20 kb, according to age, organ, and the proliferative history of 
each cell (9). During a process of DNA synthesis and cell division, telomeres shorten as a 
result of the incomplete replication of linear chromosomes, the so-called ‘end-replication 
problem’. To prevent degradation by exonucleases or processing as damaged DNA, the 
telomere 30 single-strand overhang folds back into the D-loop of duplex telomeric DNA to 
form a protective ‘T-loop’, which is reinforced with TRF2 and other telomeric DNA-binding 
proteins named shelterin (37). Telomerase is a complex of a reverse transcriptase protein 
encoded by the TERT (telomerase reverse transcriptase) gene and a template RNA TERC 
(telomerase RNA component). Telomerase can add telomeric repeats onto the chromosome 
ends, and prevents the replication-dependent loss of telomere and cellular senescence in 
highly proliferative cells of the germline and cancer cells. However, some tumour cells do not 
express telomerase activity; the stabilization of telomeres is maintained by telomerase 
independent mechanism, an 'alternative lengthening of telomeres' (ALT), when the G-strand 
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overhang invade the loop structure and act as the template for its elongation (38, 39). Hence, 
even if most human cancers use telomerase as their telomere maintenance mechanism, some 
use an alternative lengthening of telomeres (ALT) mechanism. The latter especially occurs 
most often in tumors with complex karyotypes, astrocytic brain tumours and osteosarcomas. 
Therefore, at least two mechanisms of telomere maintenance, telomerase activity and the 
recombination- based ALT, may be more or less prevalent in different tissues undergoing 
tumour formation, leading to the observed differences (40, 41). In human tumours a 
hypervariability of telomere length was observed (42, 43, 44), with only few studies 
conducted to analyze telomere length variations in brain tumors (44, 45, 46, 47, 48). 
However, determination of telomere length variations in cancers may provide promising 
information for its potential role as prognostic marker in cancers. To completely ascertain this 
hypothesis, a better understanding of the molecular events underlying telomere alterations in 
tumours and histologically normal tissues adjacent to tumours should be analyzed.  
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TABLE 2 
SUMMARY OF RELEVANT FINDINGS FOR TELOMERE LENGTH IN GBMs  
Cases Controls Main findings References 
60 BT  PPBL Variable length, 41.7% longer, 21.7% shorter, 36.7% maintenance Nürnberg P et al. 1993  
12  NBT Shorter TRFs than controls Liu J et al. 1996 * 
4  
Telomerase negative GBM, 
NBT and PPBL 
Shorter TRFs in telomerase positive GBMs compared to controls.  Le S et al. 1998  
77  ALT-negative GBMs 
Longer TRFs (more than 17 kb) and significantly longer median survival in 
ALT-positive tumors than ALT-negative ones.  
Hakin-Smith V  et al. 2003  
11 NBMT  Significantly shorter TRFs in high-grade gliomas.  Maes L et al.  2007 
47  
Gliomas without telomerase 
activity and NBT 
Shorter TRFs in tumors with telomerase activity than controls. Within the 
normal range in those without telomerase activity. 80% of the progression 
GBMs exhibited reduced mean TRF length (7.747kbp) compared with NBT 
and origin tumors. In contrast, 56,7% of de novo GBMs showed mean TRF 
lengths compatible with normal values (9.4-13.2kbp) but the mean TRF 
length was significantly reduced in tumors with telomerase activity 
(8.266±0.293) compared with that in the tumors without telomerase activity 
(11.384±0.922) (P<0.05). 
Hiraga S et al. 1998 
42  NBT  
Shorter TRFs than controls. The overall difference between primary and 
secondary GBM telomere length was not statistically significant 
Harada K et al. 2000 
2 TICs lines  BTC and NTSC  Shorter TRFs than controls 
 
Castelo-Branco P et al. 2011 
 
1 TICs line NBT Shorter TRFs than controls  Marian CO et al. 2010 
8  CBTL and PNETs 
Longer  mean TRFs (8.3 ± 0.24 kb; range 7.2–8.9 kb) than PNETs but 
equal compared with the mean CBTL TRFs (8.5 ± 0.29 kb) 
Rahman R et al. 2010 
15  NBT 
Shorter TRFs than controls. Inverse correlation between telomere length 
and patients’ survival 
Current series 
BT = Brain Tumors; PPBL = Patients’ Peripheral Blood Leukocytes; Normal Brain Tissue = NBT; TRFs = Telomere Restriction Fragments; GBM = Glioblastoma 
Multiforme; ALT = Alternative Lengthening of Telomeres;  NBMT = Normal Brain and Meningeal Tissue; BTC = Bulk Tumor Cells; TIC= Tumor initiating cell; 
NTSC = Normal Tissue Stem Cells; CBTL = Constitutional Blood Telomere Length; PNETs = Primitive Neuroectodermal Tumors; * = data collected only from the 
abstract  
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Literature review 
Analysis of telomere length and its potential use as prognostic tool in GBM has been reported 
in several studies. (Table 2), but none was specifically addressed to clarify the role of 
telomere length as prognostic marker in GBM. Therefore, here we reviewed studies focused 
on telomere length in brain tumours with the aim to emphasize those findings useful to 
enhance the awareness of potential clinical role of telomeres in GBM. In 1993, Nunberg et 
al., first reported an analysis of telomere length in 60 intracranial tumor samples, including 
GBM. Probing with the 32P-labelled synthetic (TTAGGG) 3’oligonucleotide revealed length 
changes of the telomeres occurring in intracranial tumours. Among 60 samples analysed, 
41.7% showed telomere elongation, and 21.7% telomere reduction, whereas 36.7% of the 
tumours exhibited equal lengths compared with the patients' peripheral blood leukocytes 
(PPBL) (44). Years later, Liu J et al. analyzed TRFs in a series of 12 GBMs and different 
grade of astrocytomas compared to normal brain tissue. Using a Southern blot analysis, they 
observed a progressive shortening of TRFs in astrocytomas from WHO grade I to IV with 
any significant differences between primary and recurrent GBMs. These findings support the 
hypothesis that in GBM cells, the telomere repair mechanisms maintain a relative stability of 
TRFs and permit a constitutive proliferation of those malignant cells, confirming a possible 
clinical role of telomere length in GBMs (48). Morii and colleagues, analyzed telomere 
length and telomerase activity in a series of 20 gliomas (WHO grade I to IV), including 11 
GBMs. In their series, 35% of the glioma samples examined were telomerase-negative. The 
authors demonstrated that telomerase-negative gliomas had longer TRFs compared with 
telomerase positive ones, suggesting that, in addition to the telomerase-dependent 
mechanism, a telomerase-independent mechanism for telomere maintenance may be present 
in human gliomas (47). The first report describing the relationship among ALT pattern, 
telomere length, and prognosis in human GBMs, was published by a group led by Hakin-
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Smith et al.. who analyzed telomerase activity and telomere lengths in 77 GBM patients. In 
their study, nineteen (25%) of 77 tumors presented telomeres longer than 17 kb and features 
of alternative telomere lengthening (ALT phenotype) on Southern blot. ALT phenotype 
patients had a median survival of 542 days (95% CI 114–970) compared with 247 days (224–
270) in those without the ALT phenotype. In patients with non-ALT tumours, telomerase 
activity did not affect survival (median 287 [199–375] vs 236 [230–242] days, p=0·275). 
These findings suggest that ALT is associated with elongated telomeres, benign biology and 
better prognosis in GBMs (27) while telomerase activity did not correlate with survival. 
Other studies were focused on the relationship between telomerase activity and telomere 
length in brain tumors (34, 42, 49, 50). Particularly, Hiraga et al. published a wide series of 
160 tumor samples including 47 GBMs, demonstrating that tumors with high telomerase 
activity presented very short telomeres. In contrast, telomerase negative samples had TRF 
lengths compatible with normal values (34). Harada and colleagues, confirmed this 
hypothesis and analyzed possible differences between primary and secondary GBMs. 
Summarizing their findings, telomeres in tumor samples were always shorter compared with 
NBT, but not statistically significant differences between primary and secondary GBMs were 
found. Interestingly, nevertheless the latter presented significantly higher levels of telomerase 
activity and hTERT expression than the former, telomere length was  anyways shorter than 
normal brain tissue. The authors explained this apparent discrepancy suggesting that 
telomerase activation occurs late in carcinogenesis, when the high replication rate of tumor 
cells already caused the telomeres shortening. At this point, activation of telomerase 
represents the principal mechanism to escape to apoptosis and cell death. Conversely, in 
primary GBMs, shorter telomere length can be explained by a reduced telomerase activity 
that might have less influence on carcinogenesis and, hence, other unknown factors might 
facilitate their cellular immortality (50). The clinical role of telomere length or its proxies in 
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brain tumors as marker of malignant potential has been specifically addressed just in several 
studies in the groups led by Maes, Hiraga, and Le.  In a study encompassing 14 patients  with 
different grade astrocytomas, including 11 GMB, Maes et al, determined that telomere 
length, compared with controls, was reduced in the high-grade tumours, such as GBMs, while 
was unchanged in the low-grade astrocytomas, suggesting that telomerase activity and 
hTERT, together with the telomere length can be an index of malignancy itself in intracranial 
tumors (49). Similar results were reported by others investigators who reported that 
telomerase activity is frequently detected in malignant astrocytic tumors, including GBMs, 
and it is associated to shorter telomeres (34, 42). These results suggested that telomerase 
activity and shorter telomeres detected in the more malignant stages of tumor progression can 
be useful as markers for malignancy of human gliomas. Finally, Rahman et al. compare 
telomere length with both constitutional blood and tumours of neuroectodermal origin. In 
their paper, Authors, demonstrated that the mean telomere length from tumors of of glial 
origin is significantly longer compared with neuroectodermal tumors and did not differ 
significantly from the mean blood telomere length from four patients (51). One of main 
difficulties to assess the role of telomere in GBM depend on marked heterogeneity at cellular 
and molecular levels of this neoplasm. Increasing evidences from the literature support the 
concept that a subpopulation of cancer cells in each tumor has greater potential of cancer 
initiation and repopulation (52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62). These cells are called 
cancer stem cells (CSCs) or tumor-initiating or propagating cells because they share some 
critical characteristics with normal stem cells, including the capacities for self-renewal, multi-
lineage differentiation, and maintained proliferation (63, 64, 65, 66, 67, 68). For this reason, 
recently, several authors focused their interest to the analysis of different pattern of telomere 
length and telomerase activity within GBMs tumor initiating cells (TICs). According to their 
specific biological characteristics, different from  that of the other bulk tumor cells, they 
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represent a little tumor cell subpopulation that is thought to be responsible of the tumor 
progression. In a recent study, Castelo-Branco et al. suggested that telomerase-dependent 
telomere length maintenance in high grade gliomas and neuroblastomas might be critical only 
to the survival of the self-renewing TIC tumor subpopulation and not to the bulk of tumor 
cells or the corresponding tissue stem cells. Authors demonstrated that TICs from GBM and 
NBL samples, possess high levels of hTERT and telomerase activity, accompanied by very 
short telomeres. Conversely, the majority of bulk tumor cells, normal neural stem cells and 
neural crest–like stem cells, have longer telomeres and undetectable telomerase activity 
(probably due to low hTERT expression) (69). These data support the hypothesis that tumors, 
including GBMs, are composed of a heterogeneous group of cells with different telomere 
maintenance. These findings are consistent with those of Marian et al. who reported that 
telomere length in GBM tumor cells and in GBM TICs were shorter (∼3.5kb), than normal 
brain cells telomeres. Furthermore, this study clearly show that the average telomere lengths 
of GBM tumor cells are approximately three times shorter compared to normal human brain 
cells (∼3.5 kb vs. ∼10) (70). According to the literature, the presence of shorter telomeres 
suggests a late activation of telomerase during the carcinogenesis by all tumor cells that can 
escape crisis. In these cells, telomere length is initially short and, in a late stage, following 
telomerase activation, tend to become longer. This mechanism seems to be responsible of 
TIC immortalization and, subsequently, tumor progression. 
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Conclusions 
GBM research is being conducted worldwide at a remarkable pace, with some of the more 
recent promising studies focused on identification of aberrant genetic events and signalling 
pathways, tumor stem cell identification and characterization, modulation of tumor 
immunological responses, combination therapies, and understanding of the rare long-term 
survivors. Identification of additional indicators will enable better patients’ stratification and 
individualization of treatment, is needed to more accurately determine the patient’s prognosis 
and to identify novel therapeutic approaches that can optimize the patient’s outcome. A 
growing body of knowledge suggest a potential role of telomere length in different tumors. 
Nevertheless, even if its clinical use its not completely established, a number of studies 
demonstrated that it can be helpful to patients stratification, to provide useful information 
about patients prognosis and, in some case, to suggest new therapeutic strategies in cancer 
diseases. The present review shows that the potential clinical use of telomere length 
information for the prognosis of GBM has been recognized and continues to be validated. 
Although not entirely consistent in the type of telomere alteration, i.e., attrition vs. 
elongation, and unclear on the underlying mechanisms, multiple studies in brain tumors have 
shown that telomere dysfunctions are associated with parameters of clinical outcome in 
patients with GBMs. A possible explanation for these interesting discrepancies in brain 
tumors is the fact that different expression and/or altered regulation of telomerase expression 
in tumor cells may reflect the underlying biology of telomere maintenance and its 
dysfunction over time. In telomerase positive tumor cells, telomere length is balanced by 
telomere shortening due to cell division and telomere elongation by telomerase. In mortal 
cells, telomeres shorten during proliferation and hence can be considered as a marker for the 
replicative capacity of cells in vitro. At crisis, the telomeres are at critical length, and the 
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integrity of the chromosomes declines with every subsequent cell division. At this point, 
telomere length is maintained by telomerase activity that can be influenced in different ways 
and by various factors. This capacity keeps tumour cells proliferating and growing by the 
stabilization of their telomeres which is essential to maintain the unlimited dividing potential 
and to escape ‘crisis’. (8, 34, 71). Therefore,  understanding the context and mechanisms by 
which telomeres length contribute to cancer development was the next logical research step 
and  may represent an interesting research field in order to elucidate GBMs biology. Moving 
toward the study of molecular mechanisms controlling telomere length, included telomerase 
and ALT, will not only provide insight into the complex etiology of cancer but also promises 





Graph showing inverse correlation between telomere length and survival. 
P < 0.01 
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